IFRX

InflaRx N.V.

IFRX, USA

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

https://www.inflarx.de

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IFRX
stock
IFRX

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of "Moderate Buy" from Analysts MarketBeat

Read more →
IFRX
stock
IFRX

InflaRx (NASDAQ:IFRX) Downgraded to "Hold" Rating by Leerink Partnrs MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$11.6284

Analyst Picks

Strong Buy

5

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.55

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-27.03 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-18.82 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-38,304.38 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.44

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 24.00% of the total shares of InflaRx N.V.

1.

Suvretta Capital Management, LLC

(9.5708%)

since

2025/06/30

2.

683 Capital Management LLC

(3.6533%)

since

2025/06/30

3.

RA Capital Management, LLC

(2.9126%)

since

2025/06/30

4.

Eversept Partners, LLC

(2.4214%)

since

2025/06/30

5.

Woodline Partners LP

(1.1089%)

since

2025/06/30

6.

Ikarian Capital, LLC

(1.0406%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(1.0242%)

since

2025/06/30

8.

Adage Capital Partners Gp LLC

(0.4887%)

since

2025/06/30

9.

Dafna Capital Management LLC

(0.2952%)

since

2025/06/30

10.

BOOTHBAY FUND MANAGEMENT, LLC

(0.2333%)

since

2025/06/30

11.

UBS O'Connor LLC

(0.2214%)

since

2025/06/30

12.

Squarepoint Ops LLC

(0.2156%)

since

2025/06/30

13.

Commonwealth Equity Services Inc

(0.2126%)

since

2025/06/30

14.

Virtu Financial LLC

(0.0892%)

since

2025/06/30

15.

GSA Capital Partners LLP

(0.0855%)

since

2025/06/30

16.

A4Investments SICAV SIF ACCI IlanaA2EURH

(0.0758%)

since

2025/08/31

17.

Birchview Capital, LP

(0.0738%)

since

2025/06/30

18.

Geode Capital Management, LLC

(0.0645%)

since

2025/06/30

19.

Fidelity Nasdaq Composite Index

(0.0645%)

since

2025/07/31

20.

HRT FINANCIAL LLC

(0.0643%)

since

2025/06/30

21.

SIMPLEX TRADING, LLC

(0.038%)

since

2025/06/30

22.

CIBC World Markets Inc.

(0.0369%)

since

2025/06/30

23.

Azimut Trend

(0.0033%)

since

2025/06/30

24.

AZ Fd1 AZ Allc Global Agsv A-AZ USD C

(0.0033%)

since

2025/07/31

25.

Azimut Trading

(0.0004%)

since

2025/06/30

26.

Azimut Strategic Trend

(0.0003%)

since

2025/06/30

27.

Azimut Scudo

(0.0001%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1586

Latest Release

Date

2025-09-30

EPS Actual

-0.18

EPS Estimate

-0.1511

EPS Difference

-0.0289

Surprise Percent

-19.1264%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.